De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
The present invention relates to Shiga toxin A Subunit derived polypeptides and cell-targeting molecules comprising amino acid substitutions which equip the polypeptides with 1) de-immunization; 2) reduced, protease-cleavage sensitivity; and/or 3) a heterologous epitope cargo(s) while retaining Shiga toxin function(s), such as, e.g., potent cytotoxicity. Certain polypeptides of the invention exhibit reduced immunogenic potential in mammals and/or are capable of delivering an epitope to an MHC class molecule of a cell in which the polypeptide is present. Certain molecules comprising a polypeptide of the invention are well-tolerated by mammals while retaining one or more of the features mentioned above. The Shiga toxin polypeptides of the invention have uses as components of cell-targeting molecules for selectively killing specific cells; for selectively delivering cargos to specific cells, and as therapeutic and/or diagnostic molecules for treating and diagnosing a variety of conditions, including cancers, immune disorders, and microbial infections.
1. A Shiga toxin effector polypeptide comprising an amino acid sequence having at least 90% identity to amino acids 1 to 251 of SEQ ID NO: 1;
wherein the amino acid sequence comprises amino acid substitutions V54I, R55L, I57F, P59F, E60T, E61L, S45I, G110A, R188A, C242S, R248A and R251A according to SEQ ID NO: 1; and
wherein the amino acid sequence comprises an asparagine at the amino acid residue corresponding to position 75 of SEQ ID NO: 1, a tyrosine at the amino acid residue corresponding to position 77 of SEQ ID NO: 1, a tyrosine at the amino acid residue corresponding to position 114 of SEQ ID NO: 1, a glutamate at the amino acid residue corresponding to position 167 of SEQ ID NO: 1, an arginine at the amino acid residue corresponding to position 170 of SEQ ID NO: 1, an arginine at the amino acid residue corresponding to position 176 of SEQ ID NO: 1, and a tryptophan at the amino acid residue corresponding to position 203 of SEQ ID NO: 1.
2. The Shiga toxin effector polypeptide according to claim 1 , wherein the amino acid sequence has at least 95% sequence identity to amino acids 1 to 251 of SEQ ID NO: 1.
3. The polypeptide of claim 1 , where the polypeptide comprises an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 13.
4. A Shiga toxin effector polypeptide comprising an amino acid sequence having at least 98% sequence identity to SEQ ID NO: 13.
5. A cell-targeting molecule comprising
i) a binding region capable of specifically binding an extracellular target biomolecule physically coupled to the cellular surface of a cell, and
ii) the Shiga toxin effector polypeptide of claim 1 .
6. The cell-targeting molecule of claim 5 , wherein the binding region is fused to the carboxy terminus of the Shiga toxin effector polypeptide to form a single, continuous polypeptide.
7. The cell-targeting molecule of claim 5 , wherein the binding region comprises an immunoglobulin-type binding region.
8. The cell-targeting molecule of claim 7 , wherein the immunoglobulin-type binding region comprises a polypeptide selected from: single-domain antibody fragment, single-chain variable fragment, antibody variable fragment, complementary determining region 3 fragment, constrained FR3-CDR3-FR4 polypeptide, Fd fragment, antigen-binding fragment, fibronectin-derived 10th fibronectin type III domain, tenascin type III domain, ankyrin repeat motif domain, low-density-lipoprotein-receptor-derived A-domain, lipocalin, Kunitz domain, Protein-A-derived Z domain, gamma-B crystallin-derived domain, ubiquitin-derived domain, Sac7d-derived polypeptide, Fyn-derived SH2 domain, miniprotein, C-type lectin-like domain scaffold, a heavy-chain antibody domain derived from a camelid VHH fragment, heavy-chain antibody domain derived from cartilaginous fish, immunoglobulin new antigen receptor (IgNAR), VNAR fragment, multimerizing scFv fragment, bivalent minibody, bispecific tandem scFv, bispecific tandem VHH, and bispecific minibody.
9. The cell-targeting molecule of claim 5 , which comprises the linker peptide shown in any one of SEQ ID NO: 540-543, 544-550, and 553-559.
10. The cell-targeting molecule of claim 5 , which comprises the linker peptide shown in any one of SEQ ID NO: 540-543 and 553-557.
11. A pharmaceutical composition comprising the cell-targeting molecule of claim 5 and a pharmaceutically acceptable excipient or carrier.
12. A polynucleotide capable of encoding the cell-targeting molecule of claim 5 .
13. An expression vector comprising the polynucleotide of claim 12 .
14. A host cell comprising the polynucleotide of claim 12 .